 | • レポートコード：TPM-B04222 • 出版社/出版日：Transparency Market Research / 2018年3月 • レポート形態：英文、PDF、197ページ • 納品方法：Eメール • 産業分類：製薬・医療 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Global Site License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、神経保護の世界市場について調べ、神経保護の世界規模、市場動向、市場環境、製品別（フリーラジカル捕捉剤、グルタミン酸阻害剤、アポトーシス抑制剤、抗炎症剤、神経発育因子、金属イオンキレート剤、精神刺激薬） 分析、用途別（予防、治療）分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、関連企業情報などをまとめた調査レポートです。 ・序文・調査範囲・調査手法 ・エグゼクティブサマリー ・神経保護の世界市場動向 ・神経保護の世界市場環境 ・神経保護の世界市場規模 ・神経保護の世界市場規模：製品別（フリーラジカル捕捉剤、グルタミン酸阻害剤、アポトーシス抑制剤、抗炎症剤、神経発育因子、金属イオンキレート剤、精神刺激薬） ・神経保護の世界市場規模：用途別（予防、治療） ・神経保護の世界市場：地域別市場規模・分析 ・神経保護の北米市場規模・予測 ・神経保護のアメリカ市場規模・予測 ・神経保護の中南米市場規模・予測 ・神経保護のヨーロッパ市場規模・予測 ・神経保護のアジア市場規模・予測 ・神経保護の日本市場規模・予測 ・神経保護の中国市場規模・予測 ・神経保護のインド市場規模・予測 ・神経保護の中東市場規模・予測 ・神経保護のアフリカ市場規模・予測 ・競争状況・関連企業情報 |
Global Neuroprotection Market: Overview
This report on the Neuroprotection market analyzes the current and future scenario of the global market. Increasing incidence of neurological disorders. Product development, drug launches and initiatives for increasing awareness about Neuroprotection are the major drivers of the global Neuroprotection Market.
The Neuroprotection market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on product type, application, and geography. A detailed qualitative analysis of drivers and restraints of the market and opportunities has been provided in the market overview section. In addition, the section comprises competitive matrix and company profiles with business overview to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis, by geography and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global Neuroprotection market.
Global Neuroprotection Market: Key Segments
Based on product type, the market has been segmented into Free Radical Trapping Agents (Antioxidants), Glutamate Antagonists (Anti-Excitotoxic Agents), Apoptosis Inhibitors, Anti-inflammatory Agents, Neurotrophic Factors (NTFs), Metal Ion Chelators, Stimulants, and Others. The application segments have been analyzed based on available approved products for prevention and treatment. The market size and forecast for each of these segments have been provided for the period from 2015 to 2025, along with their respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year.
Global Neuroprotection Market: Regional Outlook
Geographically, the global Neuroprotection market has been categorized into five major regions and the key countries in the respective region: North America (the U.S., Canada), Europe (the U.K., Germany, France, Spain, Italy, Russia, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America) and Middle East & Africa (South Africa, GCC countries, Israel, and Rest of Middle East & Africa). The market size and forecast for each of these regions and the mentioned countries have been provided for the period from 2015 to 2025, along with their respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year. The research study also covers the competitive scenario in these regions.
Companies Mentioned in Report
The report also profiles major players in the global Neuroprotection market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. The major players in the Neuroprotection Market are, Daiichi Sankyo Company, Eli Lilly and Company, Allergan plc, Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Novartis AG, AstraZeneca plc, Astrocyte Pharmaceuticals, Inc., F. Hoffmann-La Roche AG, Biogen Inc., and other prominent players.
The global Neuroprotection market is segmented as given below:
Global Neuroprotection Market Revenue, by Product Type, 2015–2025
Free Radical Trapping Agents (Antioxidants)
Glutamate Antagonists (Anti-Excitotoxic Agents)
Apoptosis Inhibitors
Anti-inflammatory Agents
Neurotrophic Factors (NTFs)
Metal Ion Chelators
Stimulants
Others
Global Neuroprotection Market Revenue, By Application, 2015-2025
Prevention
Treatment
Global Neuroprotection Market Revenue, By Geography, 2015–2025
North America
U.S.
Canada
Europe
Germany
France
U.K.
Spain
Italy
Russia
Rest of Europe
Asia Pacific
India
China
Japan
Australia & New Zealand
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
GCC countries
South Africa
Israel
Rest of Middle East & Africa
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
2. Assumptions and Research Methodology
2.1. Assumptions and Acronyms Used
2.2. Research Methodology
3. Executive Summary
3.1. Global Neuroprotection Market Size (US$ Mn) and Distribution, by Region, 2017 and 2025
3.2. Global Neuroprotection Market: Market Snapshot
4. Market Overview
4.1. Global Neuroprotection Market: Product Overview
4.2. Global Neuroprotection Market: Key Industry Developments
5. Market Dynamics
5.1. Drivers and Restraints Snapshot Analysis
5.2. Drivers
5.3. Restraints
5.4. Opportunities
5.5. Global Neuroprotection Market Outlook
5.6. Porters Five Forces
5.7. Pipeline Analysis
5.8. Mergers & Acquisition
5.9. Product mapping
6. Global Neuroprotection Market Analysis, by Product
6.1. Introduction
6.2. Key Insights
6.3. Global Neuroprotection Market Value Share Analysis, by Product
6.4. Global Neuroprotection Market Value (US$ Mn) Forecast , by Product
6.4.1. Free Radical Trapping Agents (Antioxidants)
6.4.2. Glutamate Antagonists (Anti-Excitotoxic Agents)
6.4.3. Apoptosis Inhibitors
6.4.4. Anti-inflammatory Agents
6.4.5. Neurotrophic Factors (NTFs)
6.4.6. Metal Ion Chelators
6.4.7. Stimulants
6.4.8. Others
6.5. Global Neuroprotection Market Attractiveness, by Product
7. Global Neuroprotection Market, By Application
7.1. Global Neuroprotection Market Value Share Analysis, by Application
7.2. Global Neuroprotection Market Value (US$ Mn) Forecast, by Application
7.2.1. Prevention
7.2.2. Treatment
7.3. Global Neuroprotection Market Attractiveness Analysis, by Application
7.3.1. Prevention
7.3.2. Treatment
8. Global Neuroprotection Market Analysis, by Region
8.1. Global Neuroprotection Market Forecast, by Region, 2015–2025
8.1.1. North America
8.1.2. Europe
8.1.3. Asia Pacific
8.1.4. Latin America
8.1.5. Middle East & Africa
8.2. Global Neuroprotection Market Value Share Analysis, by Region
8.3. Global Neuroprotection Market Attractiveness Analysis, by Region
9. North America Neuroprotection Market Analysis
9.1. North America Neuroprotection Market Key Findings
9.2. North America Neuroprotection Market Overview
9.3. North America Neuroprotection Market Value Share Analysis, by Product
9.3.1. Free Radical Trapping Agents (Antioxidants)
9.3.2. Glutamate Antagonists (Anti-Excitotoxic Agents)
9.3.3. Apoptosis Inhibitors
9.3.4. Anti-inflammatory Agents
9.3.5. Neurotrophic Factors (NTFs)
9.3.6. Metal Ion Chelators
9.3.7. Stimulants
9.3.8. Others
9.4. North America Neuroprotection Market Value Share Analysis, by Application
9.4.1. Prevention
9.4.2. Treatment
9.5. North America Neuroprotection Market Forecast, by Country
9.5.1. U.S.
9.5.2. Canada
9.6. North America Neuroprotection Market Attractiveness Analysis
9.6.1. By Product
9.6.2. By Application
9.6.3. By Country
9.7. Trends
10. Europe Neuroprotection Market Analysis
10.1. Europe Neuroprotection Market Key Findings
10.2. Europe Neuroprotection Market Overview
10.3. Europe Neuroprotection Market Value Share Analysis, by Product
10.3.1. Free Radical Trapping Agents (Antioxidants)
10.3.2. Glutamate Antagonists (Anti-Excitotoxic Agents)
10.3.3. Apoptosis Inhibitors
10.3.4. Anti-inflammatory Agents
10.3.5. Neurotrophic Factors (NTFs)
10.3.6. Metal Ion Chelators
10.3.7. Stimulants
10.3.8. Others
10.4. Europe Neuroprotection Market Value Share Analysis, by Application
10.4.1. Prevention
10.4.2. Treatment
10.5. Europe Neuroprotection Market Forecast, by Country
10.5.1. Germany
10.5.2. U.K.
10.5.3. France
10.5.4. Italy
10.5.5. Spain
10.5.6. Russia
10.5.7. Rest of Europe
10.6. Europe Neuroprotection Market Attractiveness Analysis
10.6.1. By Product
10.6.2. By Application
10.6.3. By Country
10.7. Trends
11. Asia Pacific Neuroprotection Market Analysis
11.1. Asia Pacific Neuroprotection Market Key Findings
11.2. Asia Pacific Neuroprotection Market Overview
11.3. Asia Pacific Neuroprotection Market Value Share Analysis, by Product
11.3.1. Free Radical Trapping Agents (Antioxidants)
11.3.2. Glutamate Antagonists (Anti-Excitotoxic Agents)
11.3.3. Apoptosis Inhibitors
11.3.4. Anti-inflammatory Agents
11.3.5. Neurotrophic Factors (NTFs)
11.3.6. Metal Ion Chelators
11.3.7. Stimulants
11.3.8. Others
11.4. Asia Pacific Neuroprotection Market Value Share Analysis, by Application
11.4.1. Prevention
11.4.2. Treatment
11.5. Asia Pacific Neuroprotection Market Forecast, by Country
11.5.1. China
11.5.2. India
11.5.3. Japan
11.5.4. Australia & New Zealand
11.6. Asia Pacific Neuroprotection Market Attractiveness Analysis
11.6.1. By Product
11.6.2. By Application
11.6.3. By Country
11.7. Trends
12. Latin America Neuroprotection Market Analysis
12.1. Latin America Neuroprotection Market Key Findings
12.2. Latin America Neuroprotection Market Overview
12.3. Latin America Neuroprotection Market Value Share Analysis, by Product
12.3.1. Free Radical Trapping Agents (Antioxidants)
12.3.2. Glutamate Antagonists (Anti-Excitotoxic Agents)
12.3.3. Apoptosis Inhibitors
12.3.4. Anti-inflammatory Agents
12.3.5. Neurotrophic Factors (NTFs)
12.3.6. Metal Ion Chelators
12.3.7. Stimulants
12.3.8. Others
12.4. Latin America Neuroprotection Market Value Share Analysis, by Application
12.4.1. Prevention
12.4.2. Treatment
12.5. Latin America Neuroprotection Market Forecast, by Country
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Rest of LATAM
12.6. Latin America Neuroprotection Market Attractiveness Analysis
12.6.1. By Product
12.6.2. By Application
12.6.3. By Country
12.7. Trends
13. MEA Neuroprotection Market Analysis
13.1. MEA Neuroprotection Market Key Findings
13.2. MEA Neuroprotection Market Overview
13.3. MEA Neuroprotection Market Value Share Analysis, by Product
13.3.1. Free Radical Trapping Agents (Antioxidants)
13.3.2. Glutamate Antagonists (Anti-Excitotoxic Agents)
13.3.3. Apoptosis Inhibitors
13.3.4. Anti-inflammatory Agents
13.3.5. Neurotrophic Factors (NTFs)
13.3.6. Metal Ion Chelators
13.3.7. Stimulants
13.3.8. Others
13.4. MEA Neuroprotection Market Value Share Analysis, by Application
13.4.1. Prevention
13.4.2. Treatment
13.5. MEA Neuroprotection Market Forecast, by Country
13.5.1. GCC Countries
13.5.2. South Africa
13.5.3. Israel
13.5.4. Rest of MEA
13.6. North America Neuroprotection Market Attractiveness Analysis
13.6.1. By Product
13.6.2. By Application
13.6.3. By Country
13.7. Trends
14. Competition Landscape
14.1. Global Neuroprotection Market Share Analysis, by Company (2016)
14.2. Company Profiles
14.2.1. Daiichi Sankyo Company
14.2.1.1. Overview (HQ, Employee Strength, Business Segments)
14.2.1.2. Financials
14.2.1.3. Recent Developments
14.2.1.4. Strategy
14.2.2. Eli Lilly and Company
14.2.2.1. Overview (HQ, Employee Strength, Business Segments)
14.2.2.2. Financials
14.2.2.3. Recent Developments
14.2.2.4. Strategy
14.2.3. Allergan plc.
14.2.3.1. Overview (HQ, Employee Strength, Business Segments)
14.2.3.2. Financials
14.2.3.3. Recent Developments
14.2.3.4. Strategy
14.2.4. Dr. Reddy’s Laboratories Ltd.
14.2.4.1. Overview (HQ, Employee Strength, Business Segments)
14.2.4.2. Financials
14.2.4.3. Recent Developments
14.2.4.4. Strategy
14.2.5. Teva Pharmaceutical Industries Ltd.
14.2.5.1. Overview (HQ, Employee Strength, Business Segments)
14.2.5.2. Financials
14.2.5.3. Recent Developments
14.2.5.4. Strategy
14.2.6. Novartis AG
14.2.6.1. Overview (HQ, Employee Strength, Business Segments)
14.2.6.2. Financials
14.2.6.3. Recent Developments
14.2.6.4. Strategy
14.2.7. AstraZeneca plc.
14.2.7.1. Overview (HQ, Employee Strength, Business Segments)
14.2.7.2. Financials
14.2.7.3. Recent Developments
14.2.7.4. Strategy
14.2.8. AstraZeneca plc.
14.2.8.1. Overview (HQ, Employee Strength, Business Segments)
14.2.8.2. Financials
14.2.8.3. Recent Developments
14.2.8.4. Strategy
14.2.9. Astrocyte Pharmaceuticals, Inc.
14.2.9.1. Overview (HQ, Employee Strength, Business Segments)
14.2.9.2. Financials
14.2.9.3. Recent Developments
14.2.9.4. Strategy
14.2.10. F. Hoffmann-La Roche AG
14.2.10.1. Overview (HQ, Employee Strength, Business Segments)
14.2.10.2. Financials
14.2.10.3. Recent Developments
14.2.10.4. Strategy
14.2.11. Biogen Inc.
14.2.11.1. Overview (HQ, Employee Strength, Business Segments)
14.2.11.2. Financials
14.2.11.3. Recent Developments
14.2.11.4. Strategy
Table 01: Neuroprotection Market: Pipeline Analysis
Table 02: Neuroprotection Market: Pipeline Analysis
Table 03: Neuroprotection Market: Pipeline Analysis
Table 04: Neuroprotection Market Product mapping
Table 05: Neuroprotection Market Product mapping
Table 06: Neuroprotection Market Mergers & Acquisitions
Table 07: Global Neuroprotection Market Size (US$ Mn) Forecast, by Product, 2015–2025
Table 08: Global Neuroprotection Market Size (US$ Mn) Forecast, by Application, 2015–2025
Table 09: Global Neuroprotection Market Size (US$ Mn) Forecast, by Region, 2015–2025
Table 10: North America Neuroprotection Market Size (US$ Mn) and Forecast, by Country, 2015–2025
Table 11: North America Neuroprotection Market Size (US$ Mn) Forecast, by Product, 2015–2025
Table 12: North America Neuroprotection Market Size (US$ Mn) Forecast, by Application, 2015–2025
Table 13: Europe Neuroprotection Market Size (US$ Mn) and Forecast, by Country, 2015–2025
Table 14: Europe Neuroprotection Market Size (US$ Mn) Forecast, by Product, 2015–2025
Table 15: Europe Neuroprotection Market Size (US$ Mn) Forecast, by Application, 2015–2025
Table 16: Asia Pacific Neuroprotection Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 17: Asia Pacific Neuroprotection Market Size (US$ Mn) Forecast, by Product, 2015–2025
Table 18: Asia Pacific Neuroprotection Market Size (US$ Mn) Forecast, by Application, 2015–2025
Table 19: Latin America Neuroprotection Market Size (US$ Mn) and Forecast, by Country, 2015–2025
Table 20: Latin America Neuroprotection Market Size (US$ Mn) Forecast, by Product, 2015–2025
Table 21: Latin America Neuroprotection Market Size (US$ Mn) Forecast, by Application, 2015–2025
Table 22: Middle East & Africa Neuroprotection Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 23: Middle East & Africa Neuroprotection Market Size (US$ Mn) Forecast, by Product, 2015–2025
Table 24: Middle East & Africa Neuroprotection Market Size (US$ Mn) Forecast, by Application, 2015–2025